Version 1
: Received: 11 April 2024 / Approved: 15 April 2024 / Online: 15 April 2024 (08:49:18 CEST)
How to cite:
Kassab, M.M.S. Manufacture of Corallopyronin B Antibiotic from Heterogeneous Soil Environments in Egypt. Preprints2024, 2024040927. https://doi.org/10.20944/preprints202404.0927.v1
Kassab, M.M.S. Manufacture of Corallopyronin B Antibiotic from Heterogeneous Soil Environments in Egypt. Preprints 2024, 2024040927. https://doi.org/10.20944/preprints202404.0927.v1
Kassab, M.M.S. Manufacture of Corallopyronin B Antibiotic from Heterogeneous Soil Environments in Egypt. Preprints2024, 2024040927. https://doi.org/10.20944/preprints202404.0927.v1
APA Style
Kassab, M.M.S. (2024). Manufacture of <em>Corallopyronin B </em>Antibiotic from Heterogeneous Soil Environments in Egypt. Preprints. https://doi.org/10.20944/preprints202404.0927.v1
Chicago/Turabian Style
Kassab, M.M.S. 2024 "Manufacture of <em>Corallopyronin B </em>Antibiotic from Heterogeneous Soil Environments in Egypt" Preprints. https://doi.org/10.20944/preprints202404.0927.v1
Abstract
Background:
Antibiotic resistance is an urgent issue everywhere in the globe. It is necessary to look into new sources of antibiotics to address this issue.
Aim of the study:
studying the purification of Corallopyronin B from various soil conditions in Egypt, as well as the antibacterial effectiveness of Corallopyronin B in preclinical animal testing and randomized human clinical trials phases 1/2.
Type of the study:
Screening experimental study.
Methodology:
Several soil conditions in Egypt were examined to create bacterial isolates that generated the antibiotic chemical Corallopyronin B. Using reversed-phase HPLC, Myxopyronin B was purified. The test antibiotic's minimum inhibitory concentration( MIC) and in vitro antibacterial activity were ascertained using the paper disc diffusion assay and the broth microdilution technique. Furthermore, in stages 1/2 of randomized clinical trials including human and animal models, pharmacokinetics, adverse drug reactions, and the in vivo antibacterial spectrum were discovered.
Results:
The soil bacterial isolate Corallococcus coralloides DSM 2259, which was grown on a Casein yeast peptone( CYP) plate, produced Corallopyronin B from its culture supernatant. At MICs more than 100 mcg/ml, the test antibiotic inhibited the growth of many Gram -ve bacteria, including Escherichia coli, while also preventing the growth of numerous Gram +ve bacteria, with MICs ranging from 1 to 10 mcg/ml. Eukaryotic cells, on the other hand, including those in humans and fungi, were unharmed. The test antibiotic was shown to have a bactericidal effect by inhibiting bacterial DNA-dependent RNA polymerase( RNLP).
In phases 1/2 of randomized human clinical trials, when 600 mg of the dose per 70 kg of body weight was administered SC, the Cmax was 8.6 mcg/ml at Tmax 1 hour; T1/2 reached 136 min following first-order kinetics of elimination. It stopped acting around 6-7 hours after SC was administered. In the preclinical and randomized human clinical trial phases 1/2, less than 6 percent of experimental candidates had uncommon toxicity, which showed up as reduced bile flow. Protein binding with plasma albumin was detected which reached about 83%.
Conclusion:
The current work was noteworthy since it involved the production of the bactericidal antibiotic Corallopyronin B from Corallococcus coralloides DSM 2259 which was isolated from several soil environments in Egypt.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
